Shervin Assassi

Featured in: Favicon

wiley.com

bmj.com

biomedcentral.com Favicon

thelancet.com Favicon

ersjournals.com Favicon

tmc.edu

futuremedicine.com Favicon

octnews.org Favicon

onlinelibrary.wiley.com Favicon

ard.bmj.com + 2 more

Articles

Treatment Response Biomarkers for Systemic Sclerosis‐Associated Interstitial Lung Disease

Dec 23, 2024 | acrjournals.onlinelibrary.wiley.com | Elizabeth R Volkmann |Holly Wilhalme |Donald Tashkin |Jonathan Goldin |Alana Haussmann |Masataka Kuwana | +2 more

Supporting Information Filename Description acr25485-sup-0001-Disclosureform.pdfPDF document, 671.5 KB Disclosure Form acr25485-sup-0002-supinfo.docxWord 2007 document , 331.1 KB Supporting Information
Design of a Phase III, Double-Blind, Randomised, Placebo-Controlled Trial of Bi 1015550 in Patients With Progressive Pulmonary Fibrosis (Fibroneer-Ild)

Aug 13, 2024 | digitalcommons.library.tmc.edu | Toby Maher |Shervin Assassi |Arata Azuma |Vincent Cottin

INTRODUCTION: Progressive pulmonary fibrosis (PPF) includes any diagnosis of progressive fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). However, disease progression appears comparable between PPF and IPF, suggesting a similar underlying pathology relating to pulmonary fibrosis. Following positive results in a phase II study in IPF, this phase III study will investigate the efficacy and safety of BI 1015550 in patients with PPF (FIBRONEER-ILD).
Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)

Jun 27, 2024 | bmjopenrespres.bmj.com | Toby Maher |Shervin Assassi |Arata Azuma |Vincent Cottin

Interstitial lung disease Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD) Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service.
False Positive Anti-Topoisomerase I (Scl-70) Antibody Results in Clinical Practice: A Case Series From a Scleroderma Referral Center

May 24, 2024 | digitalcommons.library.tmc.edu | Brian Lam |Shervin Assassi |Julio Charles |Rana Taherian

PURPOSE: To determine if some patients who tested positive for anti-Scl-70 antibody in clinical practice, but did not have classifiable systemic sclerosis, were negative for anti-Scl-70 antibody by the more specific immunodiffusion method of testing.
Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory Therapy.

May 7, 2024 | digitalcommons.library.tmc.edu | Elizabeth R Volkmann |Holly Wilhalme |Shervin Assassi |Jonathan Goldin

OBJECTIVE: Progressive pulmonary fibrosis (PPF) is the leading cause of death in systemic sclerosis (SSc). This study aimed to develop a clinical prediction nomogram using clinical and biological data to assess risk of PPF among patients receiving treatment of SSc-related interstitial lung disease (SSc-ILD). METHODS: Patients with SSc-ILD who participated in the Scleroderma Lung Study II (SLS II) were randomized to treatment with either mycophenolate mofetil (MMF) or cyclophosphamide (CYC).
Study design of BI 1015550 for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: a plain language summary

Feb 19, 2024 | futuremedicine.com | Toby Maher |Arata Azuma |Vincent Cottin |Shervin Assassi

This is an abstract of the Plain Language Summary of Publication article. To read the full Plain Language Summary of this article, click here to view the PDF. Link to original articles hereLink to original articles hereAcknowledgmentsThe authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment related to the development of the manuscript.
Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory Therapy

Aug 18, 2023 | acrjournals.onlinelibrary.wiley.com | Elizabeth R Volkmann |Holly Wilhalme |Shervin Assassi |Jonathan Goldin

INTRODUCTION Progressive pulmonary fibrosis (PPF) is the leading cause of death in patients with systemic sclerosis (SSc) (1). Although interstitial lung disease (ILD) occurs in the majority of patients with SSc (2), the disease course can vary considerably between patients (3). Recent observational studies have demonstrated that approximately one third of patients with SSc-ILD experience PPF at 1 year (4). However, predicting which patients with SSc-ILD will develop PPF remains a challenge (3).
Autoantibody and Cancer Connection in Systemic Sclerosis: Type and Overlap Matter

Aug 8, 2023 | acrjournals.onlinelibrary.wiley.com | Shervin Assassi

Editorial Autoantibody and Cancer Connection in Systemic Sclerosis: Type and Overlap Matter First published: 08 August 2023 No abstract is available for this article. Filename Description art42669-sup-0001-Disclosureform.pdfPDF document, 196.6 KB Disclosure Form Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors.
University of Texas Health Science Center Receives NIH Grant for Combined Optical Coherence Elastography and Tomography for Assessing Skin Involvement in Systemic Sclerosis - OCT News

Jun 7, 2023 | octnews.org | Shervin Assassi

University of Texas Health Science Center Receives a 2023 NIH Grant for $388,525 for Combined Optical Coherence Elastography and Tomography for Assessing Skin Involvement in Systemic Sclerosis. The principal investigator is Shervin Assassi. Below is a summary of the proposed study. Systemic sclerosis (SSc-scleroderma) is an autoimmune disease leading to widespread fibrosis in skin and internal organs. Skin involvement is a prominent source of distress and morbidity in this disease.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

Shervin Assassi

Articles

Treatment Response Biomarkers for Systemic Sclerosis‐Associated Interstitial Lung Disease

Design of a Phase III, Double-Blind, Randomised, Placebo-Controlled Trial of Bi 1015550 in Patients With Progressive Pulmonary Fibrosis (Fibroneer-Ild)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)

False Positive Anti-Topoisomerase I (Scl-70) Antibody Results in Clinical Practice: A Case Series From a Scleroderma Referral Center

Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory Therapy.

Study design of BI 1015550 for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: a plain language summary

Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory Therapy

Autoantibody and Cancer Connection in Systemic Sclerosis: Type and Overlap Matter

University of Texas Health Science Center Receives NIH Grant for Combined Optical Coherence Elastography and Tomography for Assessing Skin Involvement in Systemic Sclerosis - OCT News

Contact details

Emails

Socials & Sites